{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:35Z","timestamp":1791414155474,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.109015","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T22:12:05Z","timestamp":1657059125000},"page":"109015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system"],"prefix":"10.1016","volume":"110","author":[{"given":"Donald C.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B.","family":"Elmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Arnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Strassels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109015_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109015_b0010","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109015_b0015","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.intimp.2022.109015_b0020","first-page":"e11246","article-title":"Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitors: a case report and review of the literature","volume":"12","author":"Ali","year":"2020","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.intimp.2022.109015_b0025","first-page":"e16035","article-title":"Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer","volume":"13","author":"De Filippis","year":"2021","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.intimp.2022.109015_b0030","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.intimp.2022.109015_b0035","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/onco.13553","article-title":"Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy","volume":"25","author":"Gergi","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.intimp.2022.109015_b0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13730-020-00454-0","article-title":"Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Lafranchi","year":"2020","journal-title":"CEN Case Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.109015_b0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/trf.16117","article-title":"Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy","volume":"61","author":"Lancelot","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.intimp.2022.109015_b0050","doi-asserted-by":"crossref","first-page":"871217","DOI":"10.3389\/fimmu.2022.871217","article-title":"Case report: thrombotic-thrombocytopenic purpura following ipilimumab and nivolumab combination immunotherapy for metastatic melanoma","volume":"13","author":"Mullally","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109015_b0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/10781552211073883","article-title":"Thrombotic thrombocytopenic purpura associated with pembrolizumab","volume":"28","author":"Nelson","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.intimp.2022.109015_b0060","first-page":"2464619","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.intimp.2022.109015_b0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.mcna.2016.09.010","article-title":"Syndromes of thrombotic microangiopathy","volume":"101","author":"Shatzel","year":"2017","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.intimp.2022.109015_b0070","unstructured":"Maintenance and Support Services Organization [Homepage on the Internet]. Medical dictionary for regulatory activities. McLean (VA): MedDRA MSSO; 2013 (Cited 2022 May 20). <http:\/\/www.meddra.org>."},{"issue":"5","key":"10.1016\/j.intimp.2022.109015_b0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomized, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2022.109015_b0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2022.109015_b0085","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.21833","article-title":"Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes","volume":"85","author":"Terrell","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.109015_b0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.20783","article-title":"Management of cancer-associated thrombotic microangiopathy: What is the right approach?","volume":"82","author":"Werner","year":"2007","journal-title":"Am. J. Hematol."},{"issue":"36","key":"10.1016\/j.intimp.2022.109015_b0095","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109015_b0100","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:51:48Z","timestamp":1761587508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"alternative-id":["S1567576922004994"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109015","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109015"}}